Bain Capital

Merida Biosciences is a biotechnology company specializing in the development of precision therapies for autoimmune diseases. It employs a protein engineering platform to create novel Fc therapeutics, which selectively target and neutralize specific antibodies, aiming to treat the root cause of antibody-driven diseases with high precision and durability.

Founded in 1992, CMIC Group specializes in providing Contract Research Organization (CRO) services for pharmaceutical companies. Based in Tokyo, Japan, the company offers a range of services including contract development and manufacturing, site management, and market services to facilitate faster drug development.

Mitsubishi Tanabe Pharma is a Japanese pharmaceutical company that develops and manufactures drugs for various indications, including immuno-inflammation, diabetes and kidney diseases, central nervous system disorders, vaccines, and over-the-counter products. Its portfolio includes Simponi for rheumatoid arthritis, Invokana for type 2 diabetes mellitus, Stelara for Crohn’s disease, Radicava for amyotrophic lateral sclerosis, Gilenya for multiple sclerosis, and Remicade for inflammatory autoimmune diseases. The company also offers vaccines such as influenza vaccine and Varicella vaccine.

Timberlyne Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for autoimmune diseases. It leverages its team's expertise in drug development to acquire promising assets targeting unmet medical needs. The company specializes in monoclonal antibodies with enhanced complement-dependent cytotoxicity, specifically targeting CD38, a protein highly expressed in various immune cells. This approach enables rapid and durable responses across a range of autoimmune diseases.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Kailera Therapeutics is a biotechnology company focused on developing innovative treatments for obesity and associated conditions. It specializes in injectable and oral GLP-1 (Glucagon-like peptide-1) therapies, aiming to provide patients with transformative health solutions.

Serán Bioscience is a contract development and manufacturing organization that specializes in providing a wide range of services to pharmaceutical and biotechnology companies. The company offers a comprehensive suite of development, analytical, and clinical manufacturing services, aimed at optimizing drug development and production processes. By catering to various aspects of pharmaceutical development, Serán Bioscience supports its clients in efficiently bringing their products to market.

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

Loyal is a biotechnology company focused on developing medicines to extend the lifespan of dogs. By creating drugs that potentially slow aging processes, they aim to delay or prevent age-related diseases such as cancer and dementia.

Avistone Pharmaceuticals is a clinical-stage biotechnology company focused on precision oncology therapeutics.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Aiolos Bio is a biotechnology company specializing in the development of therapies for respiratory diseases and immune conditions. Its primary focus is on advancing AIO-001, a monoclonal antibody therapy for moderate-to-severe asthma, designed for dosing every 6 months. The company, founded by industry veterans, aims to address unmet treatment needs and improve patient outcomes by providing more efficacious and less burdensome therapies.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE). Its lead drug candidate, PHA121, is currently in Phase 1 clinical trials.

Porus Laboratories is a pharmaceutical company specializing in the production of intermediate and active pharmaceutical ingredients for the drug industry.

Alkeus Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston that specializes in developing treatments for serious ophthalmic conditions. The company's primary focus is on addressing untreatable diseases of the eye, with its lead drug candidate being an orally delivered compound aimed at treating Stargardt disease and age-related macular degeneration. Through its innovative approach, Alkeus aims to empower medical professionals to manage symptoms of irreversible vision loss at an earlier stage in affected patients.

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with severe hematologic disorders. Its pipeline includes therapies targeting erythropoietic porphyrias, Diamond-Blackfan Anemia, anemia of myelofibrosis and chronic kidney disease, as well as polycythemia vera.

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on researching and developing transformative therapies for cardio-metabolic diseases. Founded in 2019 and based in Naarden, the Netherlands, it is developing obicetrapib, an oral, low-dose CETP inhibitor intended to lower LDL-C and potentially address statin intolerance or residual risk in patients with ASCVD or familial hypercholesterolemia on maximally tolerated statin therapy. The company aims to improve patient care in populations where approved therapies are inadequate or poorly tolerated.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Rivus Pharmaceuticals is a biopharmaceutical company focused on enhancing cardio-metabolic health. It specializes in developing controlled metabolic accelerators (CMAs) to address the root metabolic risk factors associated with cardiovascular diseases.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders affecting the body, brain, and eye. The company's pipeline is built on a platform technology that targets well-researched autoimmune and neurodegenerative disease processes triggered by the aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody designed for intravenous administration to treat autoimmune and neurodegenerative disorders. Another key candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to address neurodegenerative ophthalmic disorders. The company employs a biomarker-driven development strategy to ensure that its product candidates effectively engage the target at therapeutic doses within the intended patient tissue, while also exploring additional orphan and large market indications.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapeutics targeting chemokine receptor CXCR4. Its lead drug candidate, mavorixafor (X4P-001), is in Phase III trials for the treatment of WHIM syndrome and has shown promising results in other indications such as severe congenital neutropenia and clear cell renal cell carcinoma.

Auxilius specializes in developing clinical trial financial management software tailored for the biopharmaceutical industry. Their platform is designed to assist sponsors in tracking contract terms, budgets, and milestones efficiently. By augmenting manual business operations and accounting processes with intuitive software, Auxilius helps sponsors gain control over trial costs, manage financial risks, and optimize spending to achieve their clinical trial targets.

Avistone Pharmaceuticals is a clinical-stage biotechnology company focused on precision oncology therapeutics.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

ConvenientMD LLC is an urgent care provider that specializes in treating non-life-threatening injuries and illnesses. Founded in 2011 and based in Portsmouth, New Hampshire, the company offers a range of services including treatment for sprains, strains, fractures, cuts, colds, bronchitis, and various infections. Additionally, ConvenientMD provides preventive care such as physicals, immunizations, and on-site prescriptions, along with X-ray and laboratory services. Patients can access care without an appointment, with centers open daily from 8 am to 8 pm, ensuring prompt service with minimal wait times. The company operates multiple locations across New Hampshire, Maine, and Massachusetts, emphasizing high-quality medical care delivered by a professional team using advanced medical equipment.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.

Crinetics Pharmaceuticals is a clinical-stage company focused on discovering, developing, and commercializing therapeutics targeting peptide hormone receptors for treating rare endocrine diseases and related cancers. Its lead product candidate, paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 biased agonist in Phase I trials for acromegaly and neuroendocrine tumors.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapeutics targeting chemokine receptor CXCR4. Its lead drug candidate, mavorixafor (X4P-001), is in Phase III trials for the treatment of WHIM syndrome and has shown promising results in other indications such as severe congenital neutropenia and clear cell renal cell carcinoma.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE). Its lead drug candidate, PHA121, is currently in Phase 1 clinical trials.

AavantiBio, Inc. is a biopharmaceutical company focused on developing gene transfer and gene editing therapies aimed at treating rare genetic diseases. Incorporated in 2019 and based in Gainesville, Florida, the company primarily concentrates on Friedreich’s Ataxia, a rare inherited disorder that leads to significant cardiac and central nervous system dysfunction. AavantiBio is committed to transforming the lives of patients suffering from this condition by advancing innovative therapies that address unmet medical needs in the field of genetic disorders. The company’s efforts are directed toward both treatment development and research, with the goal of providing effective solutions for patients facing the challenges of rare diseases.

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on discovering and developing next-generation antiviral therapeutics for severe viral diseases. The company's lead candidate, AT-527, is an antiviral agent currently undergoing phase 3 clinical trials for the treatment of COVID-19, caused by the SARS-CoV-2 virus. Additionally, Atea is advancing several candidates in clinical trials, including AT-787 for hepatitis C and AT-752 for dengue, both in phase 2 trials. The company aims to provide innovative treatments for infections caused by RNA and DNA viruses, improving outcomes for patients suffering from serious viral infections. Atea Pharmaceuticals was incorporated in 2012.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

Mersana Therapeutics is a clinical-stage biopharmaceutical company that develops antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. It leverages proprietary ADC platforms, including Dolaflexin, Dolasynthen, and Immunosynthen, to create a diverse pipeline of product candidates designed to improve therapeutic benefit and address oncology indications underserved by traditional ADCs. The lead candidate XMT-1536 targets NaPi2b and is in Phase I trials for ovarian cancer, non-small cell lung cancer, and other indications. The company also advances additional programs such as Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175, reflecting its focus on next-generation ADCs. Mersana is headquartered in Cambridge, Massachusetts, and was founded in 2005.

Nurix Therapeutics is a biopharmaceutical company focused on discovering, developing, and commercializing oral small-molecule therapies that modulate cellular protein levels to treat cancer and immune disorders. It operates DELigase, an integrated discovery platform that targets E3 ligases to alter protein abundance within cells. The company's product pipeline includes targeted protein degraders such as NX-2127, an oral Bruton's tyrosine kinase degrader for relapsed or refractory B-cell malignancies, and NX-1607, an oral Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications; these are in preclinical stages. Nurix also explores inhibitors of CBL-B, an E3 ligase that regulates T cell activation. The company collaborates with major industry partners, including Gilead Sciences and Sanofi, and was founded in 2009 and is headquartered in San Francisco.

Kymera Therapeutics is a biotechnology company focused on targeted protein degradation. It employs a proprietary predictive modeling platform to discover novel small molecule therapeutics that selectively degrade disease-causing proteins.

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for rare seizure disorders and neuropsychiatric conditions. The company's lead product candidate, ganaxolone, functions as an allosteric modulator of GABAA receptors and is being developed in both intravenous and oral formulations for use in various patient populations, including adults and children. Ganaxolone is targeted for multiple indications, such as status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment-resistant depression. Marinus Pharmaceuticals emphasizes collaboration with healthcare professionals and partners to enhance patient care and improve the lives of those affected by these conditions. Founded in 2003 and headquartered in Radnor, Pennsylvania, the company is committed to advancing its therapeutic offerings through rigorous scientific research and development.

Arcutis Biotherapeutics is a biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Its lead product, ZORYVE roflumilast cream, has demonstrated symptomatic improvement in plaque psoriasis patients.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE). Its lead drug candidate, PHA121, is currently in Phase 1 clinical trials.

Kantar, a division of WPP, is a global leader in data-driven insights and consulting. With a team of 26,500 employees across 95 countries, Kantar unites diverse expertise in market research, analytics, and consulting to provide clients with comprehensive business insights. Its services span the entire consumer cycle, aiding clients in strategic decision-making. Kantar Health, a division of Kantar, specializes in data, analytics, and research for the life sciences industry, helping clients bring safe and effective treatments to patients worldwide.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, focused on developing a community-owned platform for health and DNA research. The company's primary offering is LunaDNA, a genomic and medical research knowledge database that enables individuals to share their health and DNA data for research purposes. This platform facilitates collaborations with pharmaceutical companies, insurance providers, and healthcare IT organizations to drive advancements in medical discoveries. By allowing members to contribute their health data, LunaPBC not only supports vital health research projects but also ensures that participants can share in the financial benefits arising from medical breakthroughs, fostering a sense of community ownership and engagement in the research process.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to develop medicines for severe rare diseases and cancer. It maintains a differentiated targeted oncology portfolio with lead candidates nirogacestat, a gamma secretase inhibitor, and mirdametinib, a MEK inhibitor, both in late-stage trials; the pipeline also includes BGB-3245, an oral inhibitor of activating BRAF mutations, in Phase I, and several combination programs. The company pursues collaborations with BeiGene, GlaxoSmithKline, and Allogene and has license agreements with Pfizer for nirogacestat and mirdametinib. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks aims to advance potentially registrational studies in rare tumor types and genetically defined cancers through partnerships that expand its portfolio and patient access.

nData is an IT firm specialized in development of applications for pharma companies and CRO’s.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders affecting the body, brain, and eye. The company's pipeline is built on a platform technology that targets well-researched autoimmune and neurodegenerative disease processes triggered by the aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody designed for intravenous administration to treat autoimmune and neurodegenerative disorders. Another key candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to address neurodegenerative ophthalmic disorders. The company employs a biomarker-driven development strategy to ensure that its product candidates effectively engage the target at therapeutic doses within the intended patient tissue, while also exploring additional orphan and large market indications.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.

Arcutis Biotherapeutics is a biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Its lead product, ZORYVE roflumilast cream, has demonstrated symptomatic improvement in plaque psoriasis patients.

Centrient Pharmaceuticals is a prominent company specializing in the development, production, and sale of generic intermediates, active pharmaceutical ingredients (APIs), and drug products (DP). Their product portfolio includes penicillin G, beta-lactam intermediates, semi-synthetic penicillins, isoxazoles, cephalosporins, statins, and anti-fungals. Originally founded in 1869 as the Nederlandse Gist- en Spiritusfabriek, it was previously known as DSM Sinochem Pharmaceuticals before rebranding to Centrient Pharmaceuticals in December 2018. Based in Singapore, the company has a longstanding heritage in fermentation and emphasizes sustainability in its antibiotic production, particularly focusing on next-generation statins and anti-fungals.

Vetsource operates as a provider of online home delivery pharmacy services specifically for pet care. The company sources its human-grade institutional pharmacy products directly from manufacturers, ensuring high quality and authenticity. Vetsource's offerings include prescription management, pet owner engagement, payment solutions, and data products tailored for the veterinary industry. Additionally, the company features an e-commerce platform and a mobile app that allow pet owners to conveniently purchase necessary items for their pets. Vetsource also integrates with veterinary clinics' practice management software, enhancing the delivery of medications and improving overall service efficiency for pet owners.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

Founded in Italy, Fedrigoni is a global producer of specialty papers and self-adhesive labels. The company focuses on collaborative customer service, offering made-to-measure products alongside its extensive stock collection. With operations across Europe and Asia, Fedrigoni has maintained family ownership while expanding through recessions and wars.

InflaRx is a biopharmaceutical company focused on developing novel therapeutics targeting acute and chronic inflammation. Founded by internationally recognized researchers, the company specializes in applying proprietary anti-C5a/C5aR technology to create first-in-class inhibitors of complement activation factor C5a and its receptor C5aR.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to develop medicines for severe rare diseases and cancer. It maintains a differentiated targeted oncology portfolio with lead candidates nirogacestat, a gamma secretase inhibitor, and mirdametinib, a MEK inhibitor, both in late-stage trials; the pipeline also includes BGB-3245, an oral inhibitor of activating BRAF mutations, in Phase I, and several combination programs. The company pursues collaborations with BeiGene, GlaxoSmithKline, and Allogene and has license agreements with Pfizer for nirogacestat and mirdametinib. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks aims to advance potentially registrational studies in rare tumor types and genetically defined cancers through partnerships that expand its portfolio and patient access.

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for rare seizure disorders and neuropsychiatric conditions. The company's lead product candidate, ganaxolone, functions as an allosteric modulator of GABAA receptors and is being developed in both intravenous and oral formulations for use in various patient populations, including adults and children. Ganaxolone is targeted for multiple indications, such as status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment-resistant depression. Marinus Pharmaceuticals emphasizes collaboration with healthcare professionals and partners to enhance patient care and improve the lives of those affected by these conditions. Founded in 2003 and headquartered in Radnor, Pennsylvania, the company is committed to advancing its therapeutic offerings through rigorous scientific research and development.

Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment using its proprietary Immulytic platform. This platform aims to maximize systemic immune activation against tumor antigens through viral-mediated immunogenic tumor cell killing and delivery of optimal immune-activating proteins.

Hugel, Inc. is a biopharmaceutical company based in Chuncheon-si, South Korea, specializing in the development and manufacturing of innovative medical products. The company offers a range of Botulinum Toxin products under various brand names, including Botulax and Hugel Toxin, for medical applications such as treating eyelid convulsions, severe wrinkles, upper limb stroke, and specific foot deformities in children. Additionally, Hugel produces hyaluronic acid fillers marketed under brands like Dermalax and Revigance, as well as cosmetics under the Wellage brand. The company is committed to enhancing global health and quality of life through advanced technology and creativity, operating manufacturing facilities in Shinbuk and Geodu. Founded in 2001, Hugel aims to expand its international presence in the biopharmaceutical sector.

Dicerna Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of RNA interference (RNAi)-based therapeutics. The company focuses on innovative treatments for rare inherited liver diseases, viral infections, chronic liver diseases, and cardiometabolic conditions. Utilizing its proprietary GalXC RNAi technology platform, Dicerna is advancing several key product candidates, including nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B, and programs targeting genetic liver diseases and cardiovascular conditions. Founded in 2007 and headquartered in Lexington, Massachusetts, Dicerna has established strategic collaborations with major pharmaceutical firms to enhance its research and development efforts.

QuVa Pharma, Inc. is a 503B outsourcing company that specializes in the manufacturing and supply of compounded sterile preparations. Founded in 2015 and headquartered in Sugar Land, Texas, with additional manufacturing facilities in Temple, Texas, and Bloomsbury, New Jersey, QuVa Pharma produces a range of specialty admixtures in IV bags, syringes, and specialized vials. The company focuses on delivering vital compounded medications for various therapeutic areas, including obstetrics, anesthesia, general medicine, cardiovascular care, and pain management. By serving compliance-oriented healthcare facilities across the United States, QuVa Pharma plays a crucial role in providing ready-to-use pharmaceutical products, including antibiotics, electrolytes, and anesthetics, to hospitals and long-term care facilities.

Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing cancer therapies. It concentrates on treatments that address epidermal growth factor receptor family signaling, including neratinib for HER2-positive cancers, marketed as NERLYNX, and other candidates such as PB357, an irreversible tyrosine kinase inhibitor targeting HER1, HER2 and HER4, as well as alisertib, a selective Aurora kinase A inhibitor. The company engages in licensing arrangements, including an agreement with Pfizer to develop, manufacture and commercialize neratinib products and related compounds. In addition to ongoing development, Puma Biotechnology pursues in-licensing opportunities to expand its portfolio and bring new cancer therapies to patients.

Helomics Corporation is a personalized healthcare company that develops diagnostic and tumor profiling solutions to guide cancer treatment decisions. Its Precision Cellular Analytical Platform analyzes cell cycle and proliferation data over a multiweek timeframe to support physicians in selecting effective therapies. The company offers products including ChemoFx for gynecologic cancers, BioSpeciFx biomarker tests to evaluate tumor biology and potential drug response or prognosis, GeneFx Colon for stage II colon cancer, and GeneFx Lung for early stage non-small cell lung cancer. It also provides tumor profiling services such as bioinformatics, contract research and development, and biorepository and banking. Helomics collaborates with industry partners to advance personalized oncology insights. The company was founded in 1995 and is based in Pittsburgh, Pennsylvania.

Celerion is a clinical research organization that specializes in early-stage clinical trials and applied translational medicine services for pharmaceutical and biotechnology companies worldwide. Founded in 2010 and headquartered in Lincoln, Nebraska, with additional locations in Tempe, Arizona, and West Conshohocken, Pennsylvania, Celerion focuses on translating research discoveries into actionable insights about drug effects in humans to support early drug development decisions. The company offers a range of services including global clinical research, data management, biometrics, bioanalytical services, and drug development solutions. With over 600 beds for clinical trials and experienced scientific staff, Celerion aims to expedite the market entry of new medicines through innovative strategies and efficient data generation.

Celerion is a clinical research organization that specializes in early-stage clinical trials and applied translational medicine services for pharmaceutical and biotechnology companies worldwide. Founded in 2010 and headquartered in Lincoln, Nebraska, with additional locations in Tempe, Arizona, and West Conshohocken, Pennsylvania, Celerion focuses on translating research discoveries into actionable insights about drug effects in humans to support early drug development decisions. The company offers a range of services including global clinical research, data management, biometrics, bioanalytical services, and drug development solutions. With over 600 beds for clinical trials and experienced scientific staff, Celerion aims to expedite the market entry of new medicines through innovative strategies and efficient data generation.

CRO is supporting the development and manufacturer.

Enclarity is a provider of information management and analytic software services tailored for the healthcare industry. The company addresses the challenge of maintaining accurate healthcare provider information by maintaining the largest and most current medical provider database. Its offerings include ProviderPoint, a hosted solution for healthcare providers; a version of ProviderPoint specifically for medical device manufacturers; Physician Office Attributes; ProviderLookup, a web-based search service for provider information; and Provider SelectFile, a subscription service that delivers timely provider information based on specific needs. Enclarity's solutions are utilized by several major health insurance plans, preferred provider organizations, and leading medical device manufacturers to enhance claims processing, provider directories, regulatory compliance, and marketing efforts.

Ameritox is a U.S.-based company that provides pain medication monitoring through laboratory testing and practice management resources to help clinicians coordinate care for chronic-pain patients. It offers laboratory science services, expert support, and practice-management resources, and runs research programs in collaboration with academic centers and pain clinics to redefine the field of medication monitoring. The company has developed an advanced drug monitoring framework to identify potential medication misuse while safeguarding patient care, featuring proprietary normalization and reference-based urine testing to assess treatment adherence and inform clinical decisions.

Enclarity is a provider of information management and analytic software services tailored for the healthcare industry. The company addresses the challenge of maintaining accurate healthcare provider information by maintaining the largest and most current medical provider database. Its offerings include ProviderPoint, a hosted solution for healthcare providers; a version of ProviderPoint specifically for medical device manufacturers; Physician Office Attributes; ProviderLookup, a web-based search service for provider information; and Provider SelectFile, a subscription service that delivers timely provider information based on specific needs. Enclarity's solutions are utilized by several major health insurance plans, preferred provider organizations, and leading medical device manufacturers to enhance claims processing, provider directories, regulatory compliance, and marketing efforts.

Brenntag is a leading global supplier of chemical distribution, specializing in the manufacturing, distribution, and sale of chemicals and chemical-based products. The company plays a crucial role in connecting customers and suppliers within the chemical industry, offering a wide range of products and services. Brenntag operates through two primary segments: life science and material science. The life science segment includes chemicals utilized in the production of cosmetics, food, animal nutrition, and pharmaceuticals, while the material science segment focuses on chemicals for soaps, detergents, coatings, paints, and oil and gas extraction. Geographically, Brenntag organizes its operations into four main regions: EMEA, North America, Latin America, and APAC, providing tailored solutions that encompass industrial and chemical applications, marketing, supply chain, and digital solutions for various industries.

Liberty Dialysis, LLC, based in Mercer Island, Washington, develops, owns, and operates dialysis clinics across the United States. Founded in 2002, the company is dedicated to providing quality care for patients with chronic kidney disease through a comprehensive approach that includes outreach programs and home dialysis options. Liberty Dialysis emphasizes patient education, aiming to inform patients, their families, and the community about kidney health. The company operates clinics in multiple states, including Alaska, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Indiana, Maryland, Michigan, Nevada, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Texas, Utah, Virginia, West Virginia, and Wisconsin. As of 2012, Liberty Dialysis operates as a subsidiary of Fresenius Medical Care AG & Co. KGaA.

Definity Health focuses on the development of programs and products to enhance the consumer health care experience. Definity Health develops solutions that educate patients to assist them to make decision in treatments. Definity Health is acquired by UnitedHealth Group. Definity Health was founded in 1998 and is based in Saint Louis Park, Minnesota.

Medsite operates as a comprehensive online platform for healthcare professionals, providing a range of user-friendly solutions that include medical e-commerce, information, and communication services. The company runs Medsite.com, which serves as a destination for medical books, software, journals, supplies, and electronic physician credentialing. Additionally, Medsite offers the latest medical news and a customizable finance channel, aiming to enhance the efficiency and effectiveness of medical practices. Furthermore, Medsite develops proprietary databases tailored for pharmaceutical and healthcare companies, delivering end-to-end physician e-detailing services that encompass program development, targeted recruitment, and online distribution. Through these offerings, Medsite facilitates improved online engagement and efficiencies for medical professionals.